Pfizer Inc. revenue by year
Over the 10 fiscal years shown, revenue went from $52.82B (year ended Dec 31, 2016) to $62.58B (year ended Dec 31, 2025), a compound annual growth rate of 1.9%. The fastest growth was +95.2% in the year ended Dec 31, 2021; the weakest year was −41.1% (year ended Dec 31, 2023).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $62.58B | −1.6% | Revenues | 10-K filed Feb 26, 2026 |
| Dec 31, 2024 | $63.63B | +6.8% | Revenues | 10-K filed Feb 26, 2026 |
| Dec 31, 2023 | $59.55B | −41.1% | Revenues | 10-K filed Feb 26, 2026 |
| Dec 31, 2022 | $101.17B | +24.5% | Revenues | 10-K filed Feb 27, 2025 |
| Dec 31, 2021 | $81.29B | +95.2% | Revenues | 10-K filed Feb 22, 2024 |
| Dec 31, 2020 | $41.65B | +1.8% | Revenues | 10-K filed Feb 23, 2023 |
| Dec 31, 2019 | $40.91B | +0.2% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 24, 2022 |
| Dec 31, 2018 | $40.83B | −22.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2021 |
| Dec 31, 2017 | $52.55B | −0.5% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 27, 2020 |
| Dec 31, 2016 | $52.82B | +8.1% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 28, 2019 |
Pfizer Inc. reported revenue under 2 different XBRL concepts across these years (often after the 2018 change in revenue-recognition rules, ASC 606). Each row shows the concept used, so you can judge comparability.
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Sep 27, 2026 | $16.58B | −0.4% | 10-Q filed Nov 3, 2026 |
| 3 months ended Jun 28, 2026 | $15.03B | +2.6% | 10-Q filed Aug 4, 2026 |
| 3 months ended Mar 29, 2026 | $14.45B | +5.4% | 10-Q filed May 5, 2026 |
| 3 months ended Sep 28, 2025 | $16.65B | −5.9% | 10-Q filed Nov 3, 2026 |
| 3 months ended Jun 29, 2025 | $14.65B | +10.3% | 10-Q filed Aug 4, 2026 |
| 3 months ended Mar 30, 2025 | $13.71B | −7.8% | 10-Q filed May 5, 2026 |
| 3 months ended Sep 29, 2024 | $17.70B | +31.2% | 10-Q filed Nov 4, 2025 |
| 3 months ended Jun 30, 2024 | $13.28B | +2.1% | 10-Q filed Aug 5, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 78003 (raw data). Most recent filing in this dataset: 10-Q filed Nov 3, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.